When Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion (approximately RMB 53.7 billion), the market saw not only a high-premium deal, but also a strategic positioning for the future of neuroscience.

While pharmaceutical giants are betting heavily on popular areas such as weight loss and oncology, why is Eli Lilly going against the grain and investing heavily in "wake-up" drugs?

01

Acquisition at a 41% premium

In mergers and acquisitions in the biopharmaceutical industry, the premium often directly reflects the acquirer's judgment on the value of the target asset. Eli Lilly's 40.5% premium and the transaction structure of $6.3 billion down payment + $1.5 billion CVR are by no means blindly following the trend, but are based on a deep recognition of Centessa's core asset - the OX2R agonist combination.

From the transaction structure perspective, Eli Lilly's payment method reflects both its affirmation of Centessa's existing assets and its avoidance of potential risks in clinical research, demonstrating its "sober" investment logic. According to the transaction agreement, Eli Lilly will acquire all of Centessa's issued share capital for $38 per share in cash, with an initial cash consideration of approximately $6.3 billion. This price represents a 38% premium over Centessa's closing price on the previous trading day and a 40.5% premium over its 30-day volume-weighted average price. In addition, Eli Lilly will pay up to $1.5 billion in non-transferable contingent value rights (CVRs). CVR holders can receive an additional consideration of up to $9 per share upon achievement of three milestones, bringing the potential total consideration per share to a maximum of $47, and the total transaction value to a maximum of $7.8 billion. The three milestones reportedly all revolve around Centessa's core drug candidates: first, the FDA approval of cleminorexton (formerly ORX750) or ORX142 for the treatment of narcolepsy type 2 before the fifth anniversary of the transaction's completion; second, approval for the treatment of idiopathic hypersomnia during the same period; and third, the first-time approval of either of the two drugs for any indication before January 1, 2030. This "upfront payment + CVR" structure not only guarantees short-term returns for Centessa's shareholders but also deeply links Eli Lilly's additional payments to the drug's clinical progress, effectively reducing the risk of R&D failure and highlighting Eli Lilly's prudence and clear-headedness in acquisitions.

The core factor supporting this high premium is the "best-in-class" potential of Centessa's lead drug candidate, cleminorexton (ORX750). This OX2R agonist, currently in Phase 2a clinical trials, has demonstrated best-in-class potential in the treatment of sleep-wake disorders. As an oral OX2R agonist, cleminorexton focuses on three major indications: narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). All three diseases belong to central hypersomnia disorders, and clinical needs have long been unmet. Currently, treatment options for narcolepsy and idiopathic hypersomnia are limited, with traditional drugs often suffering from slow onset of action, significant side effects, and poor efficacy. However, the company claims that cleminorexton has shown preliminary positive efficacy signals in its Phase 2a clinical trials.

Clinical data shows that cleminorexton possesses best-in-class characteristics of " high efficacy, high selectivity, and good safety ": First, it has a rapid onset of action, quickly improving symptoms of excessive daytime sleepiness and helping patients restore a normal sleep-wake cycle; second, its efficacy is dose-dependent, demonstrating statistically significant and clinically meaningful efficacy in all three indications, potentially redefining the treatment standards for sleep-wake disorders; third, it has good safety and tolerability, with no serious adverse reactions reported, and patient compliance is higher compared to traditional treatments; fourth, as an oral dosage form, it is easier for patients to take than injectable drugs, further enhancing its clinical applicability. Furthermore, cleminorexton is scheduled to begin registrational clinical trials in the first quarter of 2026. If subsequent clinical studies progress smoothly and ultimately obtain regulatory approval for market launch, this drug is expected to become the world's first oral OX2R agonist for the treatment of sleep-wake disorders, with enormous market potential. This is one of the core reasons why Eli Lilly is willing to pay a high premium.

More notably, Eli Lilly's core objective in this acquisition is not the single cleminorexton molecule, but rather Centessa's platform value and technological accumulation in the field of OX2R agonists. Carole Ho, Executive Vice President and President of Eli Lilly Neuroscience, explicitly stated: "Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience, directly intervening in the master switch of the sleep-wake cycle. Centessa has built a broad and deep portfolio to improve wakefulness for various indications. Partnering with our Centessa colleagues means we can now pursue this potential at the speed and scale it deserves." This statement clearly reveals Eli Lilly's strategic intent—OX2R, as the "master switch" regulating the sleep-wake cycle, has a revolutionary mechanism that can directly intervene in the sleep regulation pathways of the central nervous system, applicable not only to narcolepsy and idiopathic hypersomnia, but also potentially expanding into a wider range of neurological fields.

02

Why did Eli Lilly place its bet?

Eli Lilly's willingness to acquire Centessa at a high premium stems not only from the clinical potential of cleminorexton, but also from Centessa's "deep" strategic layout in the OX2R agonist field. It does not focus on a single molecule, but rather builds a complete product portfolio around the OX2R target, forming the core advantages of " deep understanding of mechanisms + expansion of multiple indications + full pipeline coverage ." This systematic strategic layout capability is the key factor that attracted Eli Lilly.

Centessa's portfolio in the OX2R agonist field is characterized by both breadth and depth, forming a complete pipeline covering preclinical and clinical stages, encompassing multiple indications including neurological, neurodegenerative, and neuropsychiatric disorders. Its core pipeline is centered on cleminorexton (ORX750), currently in Phase 2a clinical trials, focusing on the three major sleep-wake disorders of NT1, NT2, and IH, and has demonstrated best-in-class potential, with plans to initiate registration trials in 2026. In addition, Centessa has also developed two other OX2R agonists, ORX142 and ORX489. ORX142 is in the preclinical stage, focusing on neurological and neurodegenerative diseases, while ORX489 is also in the preclinical stage, targeting neuropsychiatric disorders. Furthermore, it has several undisclosed OX2R agonist assets, forming a pipeline structure of "core product leadership + early-stage asset reserves."

This "single-target, multi-indication expansion" strategy has significant competitive advantages and is the core logic behind Centessa's success. On one hand, single-target, multi-indication expansion effectively mitigates clinical development risks—compared to targeting multiple different targets, expanding multiple indications around the OX2R target allows for the sharing of drug development technology platforms, clinical data, and manufacturing processes, reducing development costs and risks. Even if clinical progress in one indication falls short of expectations, other indications can continue to be developed, ensuring the overall value of the pipeline. On the other hand, this strategy lays the foundation for building a product matrix for sleep-wake disorders in the future. With the approval and market launch of cleminorexton, Centessa can leverage its technological accumulation in the OX2R mechanism to gradually advance the development of other indications, forming a virtuous cycle of "one core product scaling up + multiple follow-up products," maximizing long-term commercial value.

Centessa's successful portfolio strategy is inseparable from its strong technological support and team execution capabilities. Leveraging its proprietary structural biology insights, Centessa has established a unique OX2R agonist design platform capable of precisely screening candidate drugs with "high activity, high selectivity, and excellent pharmacokinetics." Its candidate drug selection criteria are stringent, focusing on drug potency, selectivity, predicted pharmacokinetic characteristics, low human dosage, and rapid onset of action, ensuring that each candidate drug possesses best-in-class potential. This technological advantage enables Centessa to rapidly advance its pipeline development, building a complete OX2R agonist portfolio in a short period.

From Eli Lilly's perspective, Centessa's value lies not only in its pipeline but also in its team's expertise in the OX2R field. Dr. Mario Alberto Accardi, CEO of Centessa, stated that the team advanced the development of OX2R agonist combinations with "speed, rigor, and conviction," completing the transition from early discovery to Phase 2a clinical trials in a short period and obtaining positive preliminary data. These assets and capabilities are precisely what Eli Lilly values—Lilly possesses a globally leading clinical development, regulatory submission, and commercialization system, while Centessa's deep understanding of OX2R mechanisms can provide Eli Lilly's neuroscience pipeline with a readily available technology platform and professional talent. Through this acquisition, Eli Lilly not only gained a promising pipeline but also directly incorporated a core team with extensive experience in the orexin field, laying a talent foundation for the rapid development of related indications.

03

The "Awakening" Era of Neuroscience

Eli Lilly's $7.8 billion acquisition of Centessa is far from an isolated merger; it's a crucial component of its long-term strategy in neuroscience and a strategic microcosm of global pharmaceutical giants vying for a foothold in this "new battlefield" beyond the GLP-1 market. With competition intensifying in the GLP-1 field, neuroscience is becoming a hot topic for differentiation among multi-capital companies (MNCs). Eli Lilly's move aims to secure the revolutionary OX2R mechanism early, building a competitive barrier in neuroscience and capturing the next wave of growth.

Looking back at its recent strategic moves, Eli Lilly has consistently increased its investment in neuroscience, establishing a pipeline covering multiple sub-sectors including Alzheimer's disease, mental illness, and pain. This acquisition of Centessa represents a horizontal extension of its neuroscience pipeline, completing its portfolio in the treatment of sleep-wake disorders and forming a "multi-domain synergy, multi-target" neuroscience pipeline matrix. Among these, the most representative is the Alzheimer's drug donanemab. As an anti-amyloid antibody, this drug has demonstrated significant efficacy in clinical trials, effectively slowing cognitive decline in Alzheimer's patients and holding the potential to become a blockbuster drug in the field. Furthermore, Eli Lilly has also developed multiple drug candidates in areas such as schizophrenia and depression, gradually building a robust neuroscience R&D system.

Eli Lilly's continued investment in neuroscience stems from the enormous unmet clinical needs and vast market potential in this field , with sleep-wake disorders being a key sub-segment. Currently, the global population suffering from sleep-wake disorders is vast; narcolepsy and idiopathic hypersomnia alone number over a million worldwide. Furthermore, with the accelerated pace and increased stress of modern life, the incidence of sleep disorders continues to rise, creating an extremely urgent clinical need. However, current treatment options in this area are limited; traditional drugs are ineffective and have significant side effects, leaving a huge market gap. The emergence of OX2R agonists represents a revolutionary breakthrough in treatment, potentially filling this clinical void and creating a market worth hundreds of billions of dollars.

More importantly, the application of the OX2R mechanism extends far beyond sleep-wake disorders, holding immense potential value in a wider range of neurodegenerative diseases such as depression and Parkinson's disease. The orexin system, a crucial regulatory system of the central nervous system, not only participates in the regulation of the sleep-wake cycle but is also closely related to multiple physiological processes, including mood regulation, cognitive function, and motor control. Existing research has shown that OX2R agonists have the potential to improve the mood and sleep quality of patients with depression and alleviate drowsiness and motor dysfunction in patients with Parkinson's disease. This means that Centessa's OX2R agonist combination has the potential to expand into a broader range of indications, bringing long-term commercial returns to Eli Lilly. This potential for "single mechanism, multi-domain expansion" is one of the core values that Eli Lilly values.

From an industry perspective, Eli Lilly's acquisition reflects the differentiated competitive logic of global multinational corporations (MNCs) beyond the GLP-1 market. In recent years, the GLP-1 target has become a hot topic in the global pharmaceutical industry. Giants like Eli Lilly and Novo Nordisk have achieved rapid growth through GLP-1 drugs. However, with more and more companies entering the market, competition in the GLP-1 sector has become increasingly fierce, with intensified homogeneous competition and gradually shrinking profit margins. Against this backdrop, neuroscience, as an underdeveloped "blue ocean" field, has become an important direction for MNCs seeking new growth curves. Compared to GLP-1, neuroscience has higher technological barriers and greater R&D difficulty, effectively avoiding homogeneous competition. OX2R, as one of the most promising mechanisms in neuroscience, has naturally become the focus of competition among giants.

Eli Lilly's $7.8 billion bet is essentially a sober assessment of the future development of the neuroscience field—beyond GLP-1, neuroscience will become the next major growth area, and OX2R agonists will be the core breakthrough point in this area . Through the acquisition of Centessa, Lilly not only gained a leading OX2R pipeline and technology platform, but also improved its neuroscience layout, forming a dual-engine growth model of "GLP-1 + neuroscience," ensuring stable short-term performance growth while securing long-term development potential. This strategy of "early planning and precise positioning" demonstrates Lilly's industry insight and strategic resolve as a global pharmaceutical giant, and also provides important lessons for other MNCs' strategies.

04

Conclusion

For $7.8 billion, Eli Lilly is buying more than just a drug candidate; it's acquiring a crucial pathway to the future of neuroscience. In a time when sleep-wake disorder treatment is still in its infancy, Eli Lilly has chosen a bold, proactive approach. Whether this deal can truly awaken the market and realize its multi-billion dollar potential depends on a combination of clinical data and commercial success. For the entire industry, it sends a clear signal: the blockbuster drugs of the next decade may lie hidden within those "awakened" neurons.

https://news.yaozh.com/archive/47685.html